American Society of Hematology

Figure 4.

$Mutational analysis describing (A) heat map of mutations and (B) outgrowth of TP53 mutations on study. In the heat map, detected mutations are indicated by shaded boxes. ∗Mutations that emerged on treatment and were detected at last BM aspirate sampling before therapy discontinuation. Green, favorable mutations; Red, unfavorable mutations (dark red, TP53; light red, RAS signaling mutations). The outgrowth graph indicates the VAF of TP53 mutations that emerged on therapy plotted over time. A total of 25 emergent TP53 mutations in 12 patients were noted on study. Most (22 of 25) emergent TP53 mutations were detectable at low levels in baseline samples either using duplex sequencing or by evaluating binary alignment map files provided by Foundation Medicine. Three were not detected at baseline (red). PR, partial response; ND, no data; RD, refractory disease; SD, stable disease.$

Mutational analysis describing (A) heat map of mutations and (B) outgrowth of TP53 mutations on study. In the heat map, detected mutations are indicated by shaded boxes. ∗Mutations that emerged on treatment and were detected at last BM aspirate sampling before therapy discontinuation. Green, favorable mutations; Red, unfavorable mutations (dark red, TP53; light red, RAS signaling mutations). The outgrowth graph indicates the VAF of TP53 mutations that emerged on therapy plotted over time. A total of 25 emergent TP53 mutations in 12 patients were noted on study. Most (22 of 25) emergent TP53 mutations were detectable at low levels in baseline samples either using duplex sequencing or by evaluating binary alignment map files provided by Foundation Medicine. Three were not detected at baseline (red). PR, partial response; ND, no data; RD, refractory disease; SD, stable disease.

This Feature Is Available To Subscribers Only